Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures

Reuters

05-24

Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures

Emergent BioSolutions Inc. is currently embroiled in significant litigation following allegations of securities fraud and manufacturing failures. The company faced class action claims from stockholders in the case In re Emergent BioSolutions Inc. Securities Litigation, filed in April 2021. Additionally, in June 2021, the Lincolnshire Police Pension Fund filed a derivative complaint against certain directors and officers of Emergent, followed by a similar complaint in August 2021. The litigation centers around extensive vaccine manufacturing failures as reported by House Committees in May 2022, and related efforts to conceal these deficiencies. Settlement negotiations are ongoing, with mediation efforts taking place in early 2024. The outcome of these legal proceedings could have significant implications for Emergent's operations and reputation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000133), on May 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537239154"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537239154\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537239154?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-24 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537239154","market":"nz","top_or_hot":-1,"title":"Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emergent BioSolutions Inc. is currently embroiled in significant litigation following allegations of securities fraud and manufacturing failures. The company faced class action claims from stockholders in the case In re Emergent BioSolutions Inc. Securities Litigation, filed in April 2021. Additionally, in June 2021, the Lincolnshire Police Pension Fund filed a derivative complaint against certain directors and officers of Emergent, followed by a similar complaint in August 2021. The litigation centers around extensive vaccine manufacturing failures as reported by House Committees in May 2022, and related efforts to conceal these deficiencies. Settlement negotiations are ongoing, with mediation efforts taking place in early 2024. The outcome of these legal proceedings could have significant implications for Emergent's operations and reputation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000133), on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-24 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emergent BioSolutions Inc. is currently embroiled in significant litigation following allegations of securities fraud and manufacturing failures. The company faced class action claims from stockholders in the case In re Emergent BioSolutions Inc. Securities Litigation, filed in April 2021. Additionally, in June 2021, the Lincolnshire Police Pension Fund filed a derivative complaint against certain directors and officers of Emergent, followed by a similar complaint in August 2021. The litigation centers around extensive vaccine manufacturing failures as reported by House Committees in May 2022, and related efforts to conceal these deficiencies. Settlement negotiations are ongoing, with mediation efforts taking place in early 2024. The outcome of these legal proceedings could have significant implications for Emergent's operations and reputation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000133), on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL3RJMcR:1","article_id":"2537239154","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537239154","pubTimestamp":1748030843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emergent BioSolutions Inc. is currently embroiled in significant litigation following allegations of securities fraud and manufacturing failures. The company faced class action claims from stockholders in the case In re Emergent BioSolutions Inc. Securities Litigation, filed in April 2021. Additionally, in June 2021, the Lincolnshire Police Pension Fund filed a derivative complaint against certain directors and officers of Emergent, followed by a similar complaint in August 2021. The litigation centers around extensive vaccine manufacturing failures as reported by House Committees in May 2022, and related efforts to conceal these deficiencies. Settlement negotiations are ongoing, with mediation efforts taking place in early 2024. The outcome of these legal proceedings could have significant implications for Emergent's operations and reputation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Emergent BioSolutions因证券欺诈和制造失败面临多起诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9},"content_text":"Emergent BioSolutions Faces Multiple Lawsuits Over Securities Fraud and Manufacturing Failures\n    \n\n        Emergent BioSolutions Inc. is currently embroiled in significant litigation following allegations of securities fraud and manufacturing failures. The company faced class action claims from stockholders in the case In re Emergent BioSolutions Inc. Securities Litigation, filed in April 2021. Additionally, in June 2021, the Lincolnshire Police Pension Fund filed a derivative complaint against certain directors and officers of Emergent, followed by a similar complaint in August 2021. The litigation centers around extensive vaccine manufacturing failures as reported by House Committees in May 2022, and related efforts to conceal these deficiencies. Settlement negotiations are ongoing, with mediation efforts taking place in early 2024. The outcome of these legal proceedings could have significant implications for Emergent's operations and reputation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000133), on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory,merge,event","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}